ProMetic and Halozyme Enter Into Long-Term Supply Agreement

MONTREAL, QUEBEC, Nov 09 (MARKET WIRE) --
ProMetic Life Sciences Inc. (TSX: PLI)("ProMetic") announced today that
Halozyme Therapeutics, Inc. (Nasdaq: HALO)("Halozyme") and ProMetic have
entered into a long-term supply agreement for a proprietary synthetic
ligand affinity adsorbent manufactured by ProMetic's UK subsidiary,
ProMetic BioSciences Ltd.

The agreement is for an initial five-year term with the opportunity for
future extension. Other aspects of the agreement were not disclosed for
reasons of client confidentiality. The synthetic ligand adsorbent
provided under the supply agreement is used by Halozyme in the
manufacture of its rHuPH20 product, a recombinant version of human
hyaluronidase enzyme. ProMetic's synthetic ligand adsorbent has been used
by Halozyme throughout the development of rHuPH20 and for manufacture of
this FDA-approved product (see ProMetic's press release dated January 16
2006).

Hyaluronidase temporarily degrades hyaluronan, a space-filling, gel-like
substance that is an important structural component of tissues throughout
the body, such as skin and cartilage. The enzyme is used to facilitate
the penetration and diffusion of other drugs and fluids that are injected
under the skin or in the muscle. Additional information on hyaluronidase
may be found on Halozyme's Web site at www.halozyme.com.

"The signing of this long-term supply agreement reflects the increasing
importance of ProMetic's synthetic ligand product to Halozyme's
manufacture of rHuPH20 and the need for Halozyme to establish a secure
supply chain," stated Dr. Steve Burton, Chief Executive Officer of
ProMetic BioSciences Ltd. Dr. Burton added: "The market for Halozyme's
rHuPH20 product is expanding and ProMetic is proud to support Halozyme's
manufacturing process for this innovative product".

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and
marketing of a variety of commercial applications derived from its
proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of pathogens.
ProMetic is also active in therapeutic drug development with the mission
to bring to market effective, innovative, lower cost, less toxic products
for the treatment of hematology and cancer. Its drug discovery platform
is focused on replacing complex, expensive proteins with synthetic
"drug-like" protein mimetics. Headquartered in Montreal (Canada),
ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing
facilities in the UK and business development activities in the U.S.,
Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and
uncertainties. These statements are "forward-looking" because they are
based on our current expectations about the markets we operate in and on
various estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking statements if
known or unknown risks affect our business, or if our estimates or
assumptions turn out to be inaccurate. Such risks and assumptions
include, but are not limited to, ProMetic's ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects,
the successful and timely completion of clinical studies, the ability of
ProMetic to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process
and general changes in economic conditions. You will find a more detailed
assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 25 of ProMetic's
Annual Information Form for the year ended December 31, 2008, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to
update any forward-looking statement even if new information becomes
available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations. All amounts are
in Canadian dollars unless stated otherwise.

Contacts:
Company inquiries:
ProMetic Life Sciences Inc.
Pierre Laurin, President and CEO
+1-514-341-2115
p.laurin@prometic.com

ProMetic Life Sciences Inc.
Anne Leduc
Manager, Investor Relations & Communications
+1-514-341-2115
a.leduc@prometic.com

ProMetic BioSciences Ltd
Steve Burton
Chief Executive Officer
+44-1223-420-300
sburton@prometicbiosciences.com

Echoes Financial Network Inc.
Dominic Sicotte
+1-514-842-9551
dsicotte@echoesfinancial.com

Copyright 2009, Market Wire, All rights reserved.

-0-